Skip to main content

Table 3 Clinical outcomes

From: Relationship between high platelet reactivity on clopidogrel and long-term clinical outcomes after drug-eluting stents implantation (PAINT-DES): a prospective, propensity score-matched cohort study

  Before propensity score matching After propensity score matching
  NPR on clopidogrel (n = 1360) HPR on clopidogrel (n = 409) P Value NPR on clopidogrel (n = 395) HPR on clopidogrel (n = 395) P Value
Stent thrombosis 7 (0.5) 13 (3.2) < 0.001 3 (0.8) 13 (3.3) 0.003
Definite/ probable Stent thrombosis 4 (0.3) 6 (1.5) 0.003 2 (0.5) 6 (1.5) 0.110
All cause death 18 (1.3) 21 (5.1) < 0.001 7 (1.8) 21 (5.3) < 0.001
 Cardiac death 6 (0.4) 10 (2.4) 0.001 2 (0.5) 10 (2.5) 0.004
MI 12 (0.9) 7 (1.7) 0.085 6 (1.5) 7 (1.8) 0.526
 STEMI 4 (0.3) 5 (1.2) 0.015 2 (0.5) 5 (1.3) 0.215
 NSTEMI 10 (0.7) 3 (0.7) NS 5 (1.3) 3 (0.8) 0.734
Clinically driven TLR 40 (2.9) 26 (6.4) < 0.001 24 (6.1) 26 (6.6) 0.111
Clinically driven TVR 43 (3.2) 32 (7.8) < 0.001 25 (6.3) 32 (8.1) 0.019
Ischemic stroke 7 (0.5) 9 (2.2) < 0.001 4 (1.0) 7 (1.8) 0.093
Bleeding (BARC≥2) 36 (2.6) 12 (2.9) 0.754 11 (2.8) 11 (2.8) NS
MACCE 74 (5.4) 64 (15.6) < 0.001 37 (9.4) 62 (15.7) < 0.001
  1. Data are number of events (Kaplan-Meier estimated event rate), compared by the log-rank test
  2. NPR normal platelet reactivity, HPR high platelet reactivity, MI myocardial infarction, TLR target lesion revascularization, TVR target vessel revascularization, MACCE major adverse cardiovascular and cerebrovascular events